This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Electroencephalographic Abnormalities Associated With Antidepressant Treatment: A Comparsion of Mirtazpine, Venlafaxine, Citalopram, Reboxetine, and Amitriptyline

Andrea Sterr, MD; Frank Padberg, MD; Benedikt Amann, MD; Roland Mergl, PhD; Christoph Mulert, MD; Georg Juckel, MD; Ulrich Hegerl, MD; and Oliver Pogarell, MD

Published: February 15, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Abnormalities in electroencephalography (EEG) recordings may occur during treatment not only with antipsychotics, but also with antidepressants.1,2 Mirtazapine and venlafaxine, 2 potent novel antidepressants that are regarded as being safer in terms of neurotoxic side effects compared to tricyclic antidepressants (TCAs), have recently been associated with a proconvulsant action.3,4 To compare the occurrence of EEG abnormalities during mirtazapine and venlafaxine treatment with EEG changes during treatment with antidepressants of other substance classes, including TCAs, we retrospectively analyzed EEG recordings of 255 patients undergoing antidepressant monotherapy with mirtazapine, venlafaxine, citalopram, reboxetine, or amitriptyline.’ ‹’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 67

Quick Links: